XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference
XOMA Royalty (NASDAQ: XOMA), a biotech royalty aggregator, has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference. Chief Investment Officer Brad Sitko will deliver a presentation on Wednesday, April 9, 2025, at 10:30 AM PT.
The presentation will be accessible through a dedicated link and the investor relations section of XOMA's website. Interested parties can access the replay, which will remain available for 90 days following the event.
XOMA Royalty (NASDAQ: XOMA), un aggregatore di royalty biotecnologiche, ha annunciato la sua partecipazione alla prossima Jones Healthcare and Technology Innovation Conference. Il Chief Investment Officer Brad Sitko terrà una presentazione mercoledì 9 aprile 2025, alle 10:30 AM PT.
La presentazione sarà accessibile tramite un link dedicato e nella sezione relazioni con gli investitori del sito web di XOMA. Le parti interessate potranno accedere alla registrazione, che rimarrà disponibile per 90 giorni dopo l'evento.
XOMA Royalty (NASDAQ: XOMA), un agregador de regalías biotecnológicas, ha anunciado su participación en la próxima Jones Healthcare and Technology Innovation Conference. El Director de Inversiones Brad Sitko realizará una presentación el miércoles 9 de abril de 2025, a las 10:30 AM PT.
La presentación será accesible a través de un enlace dedicado y en la sección de relaciones con inversores del sitio web de XOMA. Las partes interesadas podrán acceder a la repetición, que estará disponible durante 90 días después del evento.
XOMA Royalty (NASDAQ: XOMA), 생명공학 로열티 집합체, 가 오는 Jones Healthcare and Technology Innovation Conference에 참여한다고 발표했습니다. 최고 투자 책임자 브래드 시트코가 2025년 4월 9일 수요일 오전 10시 30분 PT에 발표를 진행할 예정입니다.
발표는 전용 링크와 XOMA 웹사이트의 투자자 관계 섹션을 통해 접근할 수 있습니다. 관심 있는 분들은 이벤트 후 90일 동안 제공되는 재생 영상을 이용할 수 있습니다.
XOMA Royalty (NASDAQ: XOMA), un agrégateur de redevances biopharmaceutiques, a annoncé sa participation à la prochaine Jones Healthcare and Technology Innovation Conference. Le Directeur des Investissements Brad Sitko présentera une communication le mercredi 9 avril 2025, à 10h30 PT.
La présentation sera accessible via un lien dédié et dans la section des relations investisseurs du site web de XOMA. Les parties intéressées pourront accéder à la rediffusion, qui sera disponible pendant 90 jours après l'événement.
XOMA Royalty (NASDAQ: XOMA), ein Biotech-Royalty-Aggregator, hat seine Teilnahme an der bevorstehenden Jones Healthcare and Technology Innovation Conference angekündigt. Chief Investment Officer Brad Sitko wird am Mittwoch, den 9. April 2025, um 10:30 Uhr PT eine Präsentation halten.
Die Präsentation wird über einen speziellen Link und im Bereich für Investorenbeziehungen auf der Website von XOMA zugänglich sein. Interessierte Parteien können auf die Wiederholung zugreifen, die 90 Tage nach der Veranstaltung verfügbar bleibt.
- None.
- None.
EMERYVILLE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA”; NASDAQ: XOMA), the biotech royalty aggregator, announced today Chief Investment Officer, Brad Sitko, will be a featured presenter at the Jones Healthcare and Technology Innovation Conference being held April 8-9, 2025.
Mr. Sitko’s presentation will take place on Wednesday, April 9, 2025, at 10:30 AM PT. The presentation can be assessed by visiting https://bit.ly/4l7bz6m.
XOMA’s presentations can also be accessed by visiting the investor relations section of the Company’s website at www.xoma.com. A replay of each presentation will be available and archived on the site for 90 days after the event.
About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.
| XOMA Investor Contact Juliane Snowden XOMA Royalty +1 646-438-9754 juliane.snowden@xoma.com | XOMA Media Contact Kathy Vincent KV Consulting & Management kathy@kathyvincent.com |
FAQ
When is XOMA's presentation at the Jones Healthcare Conference 2025?
How long will XOMA's conference presentation replay be available?
Who will represent XOMA at the Jones Healthcare Conference 2025?
Where can investors access XOMA's Jones Healthcare Conference presentation?
